NASDAQ:APRE
Aprea Therapeutics Inc. Stock News
$5.27
-0.320 (-5.72%)
At Close: May 17, 2024
Aprea Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference
06:00am, Tuesday, 18'th May 2021
BOSTON, May 18, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant
Aprea Therapeutics to Host Virtual R&D Day on April 22, 2021
09:15am, Friday, 16'th Apr 2021
BOSTON, April 16, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the
Aprea Therapeutics Receives FDA Orphan Drug Designation for Eprenetapopt for the Treatment of Acute Myeloid Leukemia (AML)
11:15am, Thursday, 08'th Apr 2021
BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the
Aprea Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Update on Business Operations
04:15pm, Tuesday, 16'th Mar 2021
BOSTON, March 16, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the
All You Need to Know About Aprea Therapeutics, Inc. (APRE) Rating Upgrade to Buy
12:53pm, Tuesday, 23'rd Feb 2021
Aprea Therapeutics, Inc. (APRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What Makes Aprea Therapeutics, Inc. (APRE) a New Buy Stock
12:47pm, Friday, 22'nd Jan 2021
Aprea Therapeutics, Inc. (APRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aprea Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021
08:00am, Friday, 08'th Jan 2021
BOSTON, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the m
APRE Stock Price: $6 Target By Morgan Stanley
12:30pm, Tuesday, 29'th Dec 2020
Shares of Aprea Therapeutics Inc (NASDAQ: APRE) have received a target price decrease from $34 to $6 from Morgan Stanley. These are the details.
Aprea (APRE) Plunges as Late-Stage MDS Study Fails to Meet Goal
11:17am, Tuesday, 29'th Dec 2020
Aprea (APRE) down as late-stage study on lead candidate, eprenetapopt, combined with azacitidine (AZA) versus AZA alone in TP53 mutant myelodysplastic syndromes (MDS) fails.
Is Aprea Therapeutics Doomed?
12:14pm, Monday, 28'th Dec 2020
Aprea Therapeutics Inc. (NASDAQ: APRE) stock was absolutely crushed to start out the week after the company announced results from its late-stage trial evaluating the safety and efficacy of its treatm
BOSTON, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the m
BOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the
3 Stocks with Jaw-Dropping Growth Potential
10:00am, Monday, 23'rd Nov 2020
Aprea Therapeutics, Viking Therapeutics, and Vaxart could all generate life-changing returns for early shareholders.
Aprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference
08:00am, Thursday, 19'th Nov 2020
BOSTON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the
Aprea Therapeutics Reports Third Quarter 2020 Financial Results and Provides Update on Business Operations
04:15pm, Thursday, 05'th Nov 2020
BOSTON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the